- Case Report
- Open Access
Sublingual misoprostol and hyperpyrexia: case report with temperature curve
© The Author(s) 2017
Received: 2 May 2017
Accepted: 21 July 2017
Published: 26 July 2017
Misoprostol has a wide range of applications in obstetrics and gynaecology. It is widely recommended by WHO, FIGO and ACOG for the treatment of postpartum haemorrhage due to it safety and cost-effectiveness. However, usage might be associated to hyperpyrexia and shivering.
We present a 30 year old Cameroonian female gravida 1 para 1 who had a vaginal delivery at 40 weeks of gestation complicated by primary postpartum haemorrhage (PPH). PPH was managed by sublingual misoprostol that induced shivering and hyperpyrexia managed successfully with paracetamol and cooling.
The occurrence of fever and shivering should be kept in mind when administering misoprostol for PPH.
Postpartum haemorrhage (PPH) remains the most common cause of maternal mortality with uterine atony being the commonest underling aetiology [1, 2]. It accounts for nearly one-quarter of all maternal deaths worldwide and an estimated 125,000 deaths occur each year . About 50% of these deaths occur in sub-Sahara Africa alone . Researchers have for decades searched the safest, fastest and most effective pharmacological agents to manage this dreaded complication . Conventional uterotonics such as oxytocin have been the drug of choice in the first line management of PPH secondary to uterine atony. However, a major short coming has been its obligate parenteral route of administration [2, 5].
Misoprostol is an attractive alternative because of its uterotonic potency, multiple convenient routes of administration and stability at ambient temperatures . The most common side effects associated with the postpartum administration of misoprostol are shivering and pyrexia . Studies show the rates of shivering and fever to be related to the dose and route of administration. Higher rates of shivering and elevated body temperature are associated with oral and sublingual routes of administration, which achieve a higher and faster maximum plasma concentration than vaginal and rectal routes [6–8]. We report the case of a 30 year old Cameroonian female gravida 1 para 1 who had a vaginal delivery at 40 weeks of gestation complicated by primary postpartum haemorrhage (PPH). PPH was managed by sublingual misoprostol that induced shivering and hyperpyrexia managed successfully with paracetamol and cooling.
Misoprostol, a synthetic prostaglandin E1 analogue originally used for the treatment of NSAID induced peptic ulcer has been found to have a wider application in the field of obstetrics and gynaecology because of its uterotonic and cervical-maturation effects . It has been recommended for the treatment and prevention of PPH by ACOG, FIGO and WHO [9–11]. Compared to other uterotonics, misoprostol is cheap, readily available, has a longer shelf life, stable at ambient temperature, and can be administered easily. It is a very safe drug associated with transient, mild side-effects like fever, chills, nausea, vomiting, diarrhoea and abdominal pain . Collective total daily doses of 1600 Âµg have been tolerated with only mild gastrointestinal discomfort . A study done in Ecuador in 2010 showed that there was a sharp increase in temperature within 1 h of treatment, a peak in temperature 1–2 h post-treatment, and a gradual decline in temperature over a period of 3 h. Average temperatures remained above 40.0 °C for less than 2 h, and measured below 38.0 °C approximately 6 h after receiving misoprostol. In our indexed case shivering started 20 min after administration and the temperature started rising 1 h later reaching a peak of 40.3 °C 4 h later and dropping to less than 38.0 °C 12 h later. This was consistent with results of recent studies [4, 12]. Temperature elevations associated with the use of misoprostol are compatible with the hypothalamic adjustment. Prostaglandins E2 (PGE2) have been involved in the pathophysiological mechanism of endogenous fever and identified as the major mediator for inducing fever because of its interaction with the Prostaglandin E3 (PGE3) receptor. Misoprostol-induced fever mimics the PGE2 endogenous thermoregulation patterns, changing the hypothalamic adjustment in its upper segment and stimulating temperature elevation . In our patient the possibility of a postpartum infection was almost zero as our patient had no risk factor such as prolong labour, premature rupture of membranes, etc. and emergency CRP and FBC had values within normal ranges. The fever is usually treated with paracetamol, anti-inflammatory and cooling [4, 12]. In our indexed case we used paracetamol and cooling and there was a good clinical response with temperature remaining less than 38 °C after 12 h (see Fig. 1).
Hyperpyrexia associated with shivering may be associated with administration of misoprostol 600 µg, this is more common after sublingual administration. Treatment is with oral paracetamol and cooling. This common side effect should be kept in mind when administering misoprostol for postpartum haemorrhage.
PNT managed the case, PNT & JZM wrote the draft manuscript, PNT & JZM corrected the original manuscript. Both authors read and approved the final manuscript.
We express our sincere gratitude to all doctors, nurses and medical students who took part in the management of the patient. We sincerely thank Dr. Calypse Ngwasiri for proof reading the manuscript for language and spelling checks.
The authors declare that they have no competing interests” in this section.
Availability of data and materials
The datasets (details of all results) are available from the corresponding author on reasonable request.
Consent for publication
Written informed consent was obtained from the patient’s for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
Ethics approval and consent to participate
Ethical approval was obtained from Douala general hospital for publication of this case report.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Hogan MC, Foreman KJ, Naghavi M, Ahn SY, Wang M, Makela SM, et al. Maternal mortality for 181 countries, 1980-2008: a systematic analysis of progress towards Millennium Development Goal 5. Lancet Lond Engl. 2010;375(9726):1609–23.View ArticleGoogle Scholar
- Bonnet MP, Benhamou D. Management of postpartum haemorrhage. F1000Res. 2016. http://0-www.ncbi.nlm.nih.gov.brum.beds.ac.uk/pmc/articles/PMC4926727/. Accessed 28 Apr 2017.
- Tebeu P-M, Halle-Ekane G, Da Itambi M, Mbu RE, Mawamba Y, Fomulu JN. Maternal mortality in Cameroon: a university teaching hospital report. Pan Afr Med J. 2015. http://0-www.ncbi.nlm.nih.gov.brum.beds.ac.uk/pmc/articles/PMC4561158/. Accessed 28 Apr 2017.
- Durocher J, Bynum J, León W, Barrera G, Winikoff B. High fever following postpartum administration of sublingual misoprostol. BJOG. 2010;117(7):845–52.View ArticlePubMedPubMed CentralGoogle Scholar
- Mousa HA, Blum J, Abou El Senoun G, Shakur H, Alfirevic Z. Treatment for primary postpartum haemorrhage. Cochrane Database Syst Rev. 2014;(2):CD003249.Google Scholar
- Allen R, O’Brien BM. Uses of misoprostol in obstetrics and gynecology. Rev Obstet Gynecol. 2009;2(3):159–68.PubMedPubMed CentralGoogle Scholar
- Khan RU, El-Refaey H. Pharmacokinetics and adverse-effect profile of rectally administered misoprostol in the third stage of labor. Obstet Gynecol. 2003;101(5 Pt 1):968–74.PubMedGoogle Scholar
- Al-Harazi AH, Frass KA. Sublingual misoprostol for the prevention of postpartum hemorrhage. Saudi Med J. 2009;30(7):912–6.PubMedGoogle Scholar
- American College of Obstetricians and Gynecologists. ACOG Practice Bulletin: Clinical Management Guidelines for Obstetrician-Gynecologists Number 76, October 2006: postpartum hemorrhage. Obstet Gynecol. 2006;108(4):1039–47.View ArticleGoogle Scholar
- FIGO guideline. Treatment of postpartum haemorrhage with misoprostol. 2012.Google Scholar
- Hofmeyr GJ, Gülmezoglu AM, Novikova N, Linder V, Ferreira S, Piaggio G. Misoprostol to prevent and treat postpartum haemorrhage: a systematic review and meta-analysis of maternal deaths and dose-related effects. Bull World Health Organ. 2009;87(9):666–7.View ArticlePubMedPubMed CentralGoogle Scholar
- León W, Durocher J, Barrera G, Pinto E, Winikoff B. Dose and side effects of sublingual misoprostol for treatment of postpartum hemorrhage: what difference do they make? BMC Pregnancy Childbirth. 2012;12:65.View ArticlePubMedPubMed CentralGoogle Scholar